Published in J Hypertens on October 01, 2008
Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health (2010) 1.10
Impact of yoga on blood pressure and quality of life in patients with hypertension - a controlled trial in primary care, matched for systolic blood pressure. BMC Cardiovasc Disord (2013) 0.92
Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovasc Diabetol (2009) 0.91
Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ (2010) 0.84
Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract (2012) 0.83
Prevalence of metabolic syndrome among newly diagnosed hypertensive patients in the hills of Himachal Pradesh, India. Indian J Endocrinol Metab (2013) 0.81
Metabolic syndrome in hypertensive patients: An unholy alliance. World J Cardiol (2014) 0.78
Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens (2013) 0.76
Social disparities, health risk behaviors, and cancer. BMC Surg (2013) 0.75
Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: K-MetS Study. Medicine (Baltimore) (2016) 0.75
Management of hypertension and diabetes mellitus by cardiovascular and endocrine physicians: a China registry. J Hypertens (2016) 0.75
Effect of vitamins a, C, and e supplementation in the treatment of metabolic syndrome in albino rats. Biochem Res Int (2012) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke (2003) 4.63
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension (2012) 2.95
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest (2004) 2.36
Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. Hypertension (2013) 2.10
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation (2009) 1.93
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation (2003) 1.93
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J (2012) 1.77
Oscillometric estimation of central blood pressure: validation of the Mobil-O-Graph in comparison with the SphygmoCor device. Blood Press Monit (2012) 1.74
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*. J Hypertens (2006) 1.74
Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) (2007) 1.67
Effect of the venous catheter site on transpulmonary thermodilution measurement variables. Crit Care Med (2007) 1.63
Adenosine 5'-tetraphosphate is a highly potent purinergic endothelium-derived vasoconstrictor. Circ Res (2008) 1.61
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail (2004) 1.57
Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension (2005) 1.52
Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens (2008) 1.52
Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus. Biochem Biophys Res Commun (2004) 1.47
Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation (2004) 1.46
Small artery elasticity assessed by pulse wave analysis is no measure of endothelial dysfunction. J Hypertens (2007) 1.46
Angiotensinogen promoter haplotypes are associated with blood pressure in untreated hypertensives. J Hypertens (2004) 1.45
Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique. Artif Organs (2013) 1.42
The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation (2003) 1.41
[Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) (2008) 1.39
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens (2007) 1.36
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood (2004) 1.30
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant (2008) 1.23
Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med (2005) 1.19
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood (2003) 1.19
Validation of the mobil-O-Graph: 24 h-blood pressure measurement device. Blood Press Monit (2010) 1.19
Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol (2011) 1.17
Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol (2007) 1.16
Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res (2005) 1.14
High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res (2012) 1.11
Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol (2006) 1.10
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica (2012) 1.10
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res (2013) 1.09
Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol (2009) 1.08
Noninvasive evaluation of renal allograft fibrosis by transient elastography--a pilot study. Transpl Int (2010) 1.08
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol (2004) 1.07
Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun (2007) 1.06
Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Basic Res Cardiol (2011) 1.05
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings. J Hypertens (2014) 1.04
Non-invasive assessment of microvascular endothelial function by laser Doppler flowmetry in patients with essential hypertension. Atherosclerosis (2004) 1.02
Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. Eur Heart J (2010) 1.01
Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol (2011) 0.99
Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. Am J Clin Oncol (2006) 0.98
A physiogenomic approach to study the regulation of blood pressure. Physiol Genomics (2005) 0.97
Differential effects of uridine adenosine tetraphosphate on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol (2010) 0.97
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol (2008) 0.97
Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. Hum Mol Genet (2003) 0.97
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clin Sci (Lond) (2009) 0.96
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood (2011) 0.95
Isoforms of retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver. Lipids Health Dis (2008) 0.94
Characterization of polymer membranes by MALDI mass-spectrometric imaging techniques. Anal Chem (2013) 0.94
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol (2006) 0.93
Transient receptor potential channels in essential hypertension. J Hypertens (2006) 0.93
Too old to benefit from sports? The cardiovascular effects of exercise training in elderly subjects treated for isolated systolic hypertension. Kidney Blood Press Res (2007) 0.92
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica (2013) 0.92
Increased transient receptor potential channel TRPC3 expression in spontaneously hypertensive rats. Am J Hypertens (2005) 0.91
Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovasc Diabetol (2009) 0.91
Increased TRPC3 expression in vascular endothelium of patients with malignant hypertension. Mod Pathol (2009) 0.91
Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio. J Mol Med (Berl) (2003) 0.91
Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. Br J Pharmacol (2009) 0.90
Identification and quantification of diadenosine polyphosphate concentrations in human plasma. Arterioscler Thromb Vasc Biol (2003) 0.90
Emphysematous pyelonephritis in a kidney allograft. Am J Kidney Dis (2009) 0.90
Association of calcium channel blockers and mortality in haemodialysis patients. Clin Sci (Lond) (2002) 0.90
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol (2007) 0.90
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid (2012) 0.89
Hypertension and acute myocardial infarction: an overview. J Cardiovasc Med (Hagerstown) (2012) 0.88
Endogenous glycosides in critically ill patients. Crit Care Med (2003) 0.88
Renal cathepsin G and angiotensin II generation. J Hypertens (2006) 0.87
Mean platelet volume and coronary heart disease in hemodialysis patients. Kidney Blood Press Res (2002) 0.87
Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives. Arterioscler Thromb Vasc Biol (2007) 0.87
Sleep-related breathing disorders impair quality of life in haemodialysis recipients. Nephrol Dial Transplant (2002) 0.87
Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J (2011) 0.86
Convenience of ambulatory blood pressure monitoring: comparison of different devices. Blood Press Monit (2005) 0.86
Uridine adenosine tetraphosphate (Up4A) is a strong inductor of smooth muscle cell migration via activation of the P2Y2 receptor and cross-communication to the PDGF receptor. Biochem Biophys Res Commun (2011) 0.86
Inconsistency of reported uremic toxin concentrations. Artif Organs (2007) 0.86
Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res (2005) 0.86
Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol (2008) 0.85
Endogenous diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate in human myocardial tissue. Hypertension (2004) 0.85
Monocytes from spontaneously hypertensive rats show increased store-operated and second messenger-operated calcium influx mediated by transient receptor potential canonical Type 3 channels. Am J Hypertens (2007) 0.85
Increased store-operated and 1-oleoyl-2-acetyl-sn-glycerol-induced calcium influx in monocytes is mediated by transient receptor potential canonical channels in human essential hypertension. J Hypertens (2007) 0.85
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens (2014) 0.85
Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging (2011) 0.84
Transient receptor potential canonical type 3 channels and blood pressure in humans. J Hypertens (2009) 0.84
Association of transient receptor potential canonical type 3 (TRPC3) channel transcripts with proinflammatory cytokines. Arch Biochem Biophys (2007) 0.84
Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid (2008) 0.84